Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | THRB | P10828 | 1/20 | 0.79 |
| ▸ | MTOR | P42345 | 1/20 | 0.79 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.79 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.79 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.54 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9465323 | 1.00 | LMNA (0.79) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL9465332 | 1.00 | LMNA (0.79) | LMNATHRBMTORMDM2NCOA1 | |
| Cytidine SCHEMBL28159035 | 0.90 | LMNA (0.93) | LMNATHRBMTORMDM2NCOA1 | |
| Cytidine SCHEMBL28159003 | 0.89 | LMNA (0.90) | LMNATHRBMTORMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 0.88 | LMNA (1.00) | LMNATHRBMTORMDM2NCOA1 | |
| Cytarabine SCHEMBL12202579 | 0.88 | LMNA (1.00) | LMNATHRBMTORMDM2NCOA1 | |
| Cytarabine SCHEMBL329878 | 0.88 | LMNA (1.00) | LMNATHRBMTORMDM2NCOA1 | |
| Cytarabine SCHEMBL14644972 | 0.88 | LMNA (1.00) | LMNATHRBMTORMDM2NCOA1 | |
| Cytarabine SCHEMBL20546595 | 0.88 | LMNA (1.00) | LMNATHRBMTORMDM2NCOA1 | |
| Cytarabine SCHEMBL3140 | 0.88 | LMNA (1.00) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7172867-B2 | Methods of testing for allergic diseases, and therapeutic agents for treating same | GENOX RESEARCH, INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | LMNA 4011/4885THRB 4314/4885MTOR 3810/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | LMNA 3945/4885THRB 4377/4885MTOR 3750/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | LMNA 4011/4885THRB 4314/4885MTOR 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.